Apnimed, Inc. (NASDAQ:APMD – Get Free Report) has received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $50.33.
A number of research firms have recently commented on APMD. Wall Street Zen upgraded Apnimed to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings began coverage on shares of Apnimed in a research note on Tuesday, October 27th. They issued a “sell (e-)” rating for the company. Evercore began coverage on shares of Apnimed in a research report on Tuesday, August 25th. They set an “outperform” rating on the stock. Lifesci Capital started coverage on shares of Apnimed in a report on Tuesday, August 25th. They issued an “outperform” rating and a $50.00 price objective on the stock. Finally, Zacks Research upgraded Apnimed to a “hold” rating in a research note on Wednesday, August 26th.
Read Our Latest Research Report on APMD
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Apnimed stock. Integral Health Asset Management LLC bought a new position in Apnimed, Inc. (NASDAQ:APMD – Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 225,000 shares of the company’s stock, valued at approximately $4,930,000. Integral Health Asset Management LLC owned 0.54% of Apnimed as of its most recent SEC filing.
Apnimed Stock Performance
Apnimed stock opened at $17.80 on Wednesday. The business’s 50-day moving average price is $20.07. Apnimed has a 12-month low of $13.88 and a 12-month high of $35.29.
Apnimed (NASDAQ:APMD – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($1.05) EPS for the quarter. The business had revenue of $2.48 million during the quarter. As a group, equities research analysts expect that Apnimed will post -0.24 EPS for the current fiscal year.
Apnimed Company Profile
Apnimed is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea. The company aims to offer drug-based treatment options for people who may not use or benefit from existing device-based therapies. Its lead candidate, AD109, is an investigational oral combination of atomoxetine and aroxybutynin (oxybutynin) designed to help maintain upper-airway muscle activity during sleep. Apnimed has evaluated AD109 in clinical trials for obstructive sleep apnea; it is not an approved treatment.
Featured Articles
- Five stocks we like better than Apnimed
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
